Jason Konner
Overview
Explore the profile of Jason Konner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Green A, Zhou Q, Iasonos A, Zammarrelli W, Weigelt B, Ellenson L, et al.
Clin Cancer Res
. 2024 Nov;
PMID: 39561275
Purpose: Inhibition of the cyclin D-cyclin dependent kinase (CDK)4/6-INK4-retinoblastoma pathway can overcome acquired or de novo treatment resistance to endocrine monotherapy. Responses to endocrine monotherapy in advanced endometrial cancer (EC)...
2.
Lumish M, Chui M, Zhou Q, Iasonos A, Sarasohn D, Cohen S, et al.
Gynecol Oncol
. 2024 Jan;
182:75-81.
PMID: 38262242
Objective: HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but HER2-directed therapy...
3.
Friedman C, Ravichandran V, Miller K, Vanderbilt C, Zhou Q, Iasonos A, et al.
Clin Cancer Res
. 2023 Aug;
29(22):4660-4668.
PMID: 37643132
Purpose: Tumor genomic profiling is increasingly used to guide treatment strategy in patients with cancer. We integrated tumor genomic, clinical demographic, and treatment response data to assess how prospective tumor-normal...
4.
Manning-Geist B, Gnjatic S, Aghajanian C, Konner J, Kim S, Sarasohn D, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900251
We examined the safety and immunogenicity of sequential administration of a tetravalent, non-HLA (human leukocyte antigen) restricted, heteroclitic Wilms' Tumor 1 (WT1) peptide vaccine (galinpepimut-S) with anti-PD-1 (programmed cell death...
5.
Rubinstein M, Doria E, Konner J, Lichtman S, Zhou Q, Iasonos A, et al.
Gynecol Oncol
. 2022 Dec;
169:64-69.
PMID: 36512912
Introduction: Our understanding of the biologic heterogeneity of endometrial cancer has improved, but which patients benefit from single-agent versus combination immune checkpoint blockade remains unclear. Methods: We conducted a single-center,...
6.
Deng G, Bao T, Ryan E, Benusis L, Hogan P, Li Q, et al.
Integr Cancer Ther
. 2022 Jul;
21:15347354221089221.
PMID: 35861215
Purpose: Many cancer survivors experience cancer-related cognitive impairment (CRCI). We conducted a randomized controlled pilot trial of 2 types of yoga practice and evaluated their effects on participants' objective cognitive...
7.
Foulsham W, Edghill B, Julia Canestraro O, Makker V, Konner J, Abramson D, et al.
Am J Ophthalmol Case Rep
. 2022 Jul;
27:101657.
PMID: 35845747
Purpose: To report a case of central retinal vein occlusion (CRVO) in a patient being treated with a fibroblast growth factor receptor (FGFR) inhibitor. Observations: A 54-year-old female patient with...
8.
Bolton K, Chen D, Corona de la Fuente R, Fu Z, Murali R, Kobel M, et al.
Clin Cancer Res
. 2022 Jul;
28(22):4947-4956.
PMID: 35816189
Purpose: To identify molecular subclasses of clear cell ovarian carcinoma (CCOC) and assess their impact on clinical presentation and outcomes. Experimental Design: We profiled 421 primary CCOCs that passed quality...
9.
Cunningham J, Winham S, Wang C, Weiglt B, Fu Z, Armasu S, et al.
Cancer Epidemiol Biomarkers Prev
. 2021 Oct;
31(1):132-141.
PMID: 34697060
Background: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA...
10.
Chui M, Chang J, Zhang Y, Zehir A, Schram A, Konner J, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34568720
Methods: Retrospective analysis of our institutional cohort of SBTs (n = 22), LGSCs (n = 119) and high-grade serous carcinomas (HGSCs, n = 1,290) subjected to targeted massively parallel sequencing...